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Background:  The glycoprotein IIb/IIIa receptor inhibitors (GPIs) have improved the efficacy of primary percutaneous coronary interventions in 
patients with acute ST-segment-elevation myocardial infarction (STEMI) when added to aspirin and heparin. However, it is not known whether GPIs 
remains beneficial after adequate clopidogrel loading in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
Methods:  We obtained results from all randomized trials comparing GPIs (abciximab, tirofiban or eptifibatide) with placebo among STEMI patients 
scheduled for PPCI on top of a loading dose of 300-600 mg clopidogrel. The literature was scanned by formal searches of electronic databases from 
January 1990 to September 2010. Abstract lists from the main scientific meetings were also reviewed. Clinical endpoints assessed were mortality 
and reinfarction at 30 days and 6-12 months follow-up, whereas major bleeding complications were assessed as safety endpoint. No language 
restriction was applied.
Results:  We identified 7 randomized clinical trials meeting the prespecified criteria, including 6116 STEMI patients (3131 patients randomly 
assigned to GPIs and 2985 patients to placebo administration) scheduled for PPCI and pretreated with a loading dose of 300-600 mg clopidogrel. 
When compared with placebo, GPIs were not associated with a significant reduction in the odds of 30 days (OR 1.23, 95% CI 0.90-1.67, P = 0.19) 
or 6-12 months (OR 1.26, 95% CI 0.98-1.63, P = 0.07) mortality. Similarly, the rate of reinfarction was not statistically different at 30 days (OR 0.91, 
95% CI 0.63-1.31, P = 0.60) or at 6-12 months follow-up (OR 1.16; 95% CI 0.87-1.53, P = 0.32). On the contrary, GPIs did result in an increased 
risk of major bleeding complications (OR 1.60, 95% CI 1.23-2.09, P = 0.001).
Conclusion: The present meta-analysis shows that GPIs did not reduce the risks of death or reinfarction, but were associated with higher risk of 
major bleeding complications in STEMI patients undergoing PPCI and receiving a loading dose of clopidogrel. These findings do not support the 
routine utilization of GPIs on top of clopidogrel pretreatment in STEMI patients scheduled for PPCI.
